TLSA
Tiziana Life Sciences Ltd
$1.10
-2.65%
$140.0M
No data for this timeframe.
Vol
Market Cap$140.0M
Cap SizeMicro Cap
SEC Reports7
Press Releases3
Recent Activity
Jun 5, 2026
SEC
Tiziana Life Sciences filed a 6-K announcing its upcoming corporate presentation at the Jefferies Healthcare Conference
6-K — Impact 3/10
May 28, 2026
other
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
<p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a h
May 21, 2026
Press
Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a INFORM-MS trial of intranasal foralumab
Impact 7/10
May 21, 2026
SEC
Tiziana Life Sciences announced completion of patient enrollment (n=48) in its Phase 2a placebo-controlled trial (INFORM
6-K — Impact 6/10
May 19, 2026
SEC
Tiziana Life Sciences announced updated positive clinical data from its Expanded Access Program for intranasal foralumab
6-K — Impact 5/10
Apr 16, 2026
Press
Tiziana Life Sciences announced positive preclinical data from a bioRxiv preprint showing intranasal foralumab reduced n
Impact 7/10
Price Targets
Historical data — last covering-analyst action Jun 2022. No current recommendation available.
$9.00 (Jun 2022)
Current $1.10
Low $9.00
Median $9.00
High $9.00
1 analysts
$9.00
$9.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 13, 2022 | ThinkEquity | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-0.12 ▲ +19.6% | $-0.12 — $-0.12 | -1% YoY | 1 |
Latest Reports
NEUTRAL
6-K
3/10
Tiziana Life Sciences filed a 6-K announcing its upcoming corporate presentation at the Jefferies Healthcare Conference
Jun 5, 2026
BULLISH
Press
7/10
Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a INFORM-MS trial of intranasal foralumab
May 21, 2026
BULLISH
6-K
6/10
Tiziana Life Sciences announced completion of patient enrollment (n=48) in its Phase 2a placebo-controlled trial (INFORM
May 21, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 6 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
NEUTRAL
6-K
3/10
Tiziana Life Sciences filed a 6-K announcing its upcoming corporate presentation at the Jefferies He
Jun 5, 2026
BULLISH
6-K
6/10
Tiziana Life Sciences announced completion of patient enrollment (n=48) in its Phase 2a placebo-cont
May 21, 2026
BULLISH
6-K
5/10
Tiziana Life Sciences announced updated positive clinical data from its Expanded Access Program for
May 19, 2026
BULLISH
6-K
7/10
Tiziana Life Sciences reported initial quantitative PET imaging results from the first two patients
May 14, 2026
BULLISH
6-K
6/10
Tiziana Life Sciences announced positive preclinical data from a bioRxiv preprint showing that its i
Apr 16, 2026
BULLISH
6-K
6/10
Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a clinical trial of intran
Apr 14, 2026
BULLISH
6-K
7/10
Tiziana Life Sciences announced positive preclinical data showing its intranasal anti-CD3 therapy (f
Apr 1, 2026
BULLISH
7/10
Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a INFORM-MS trial of
May 21, 2026
BULLISH
7/10
Tiziana Life Sciences announced positive preclinical data from a bioRxiv preprint showing intranasal
Apr 16, 2026
BULLISH
7/10
Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a trial of intranasal fora
Apr 14, 2026
Historical analyst distribution (last covering-analyst action Jun 2022): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jun 2022. No current recommendation available.
$9.00 mean target (Jun 2022)
$9.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $1.10 |
| Target Low | $9.00 |
| Target Mean | $9.00 |
| Target Median | $9.00 |
| Target High | $9.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$-0.12 | $-0.12 | $-0.12 | -1.3% | +19.6% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 13, 2022 | ThinkEquity | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
other
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
<p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=Te
May 21, 2026
fda
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
<p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=AIFRBUDtW0vcPto
Apr 16, 2026
fda
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralu
Apr 14, 2026
fda
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
<p>BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=Zb1ZRMsZiXw1B